Etanercept

Generic Name: Etanercept

Brand Names: Enbrel, Eticovo, Benepali, Erelzi, Nepexto

Drug Type: Biotech

Chemical Formula: -

CAS Number: 185243-69-0

Unique Ingredient Identifier: OP401G7OJC

Background: Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1. The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of IgG1. Etanercept is produced by recombinant DNA technology in a Chinese hamster ovary (CHO) mammalian cell expression system. It consists of 934 amino acids. It is used to treat or manage a variety of inflammatory conditions including rheumatoid arthritis (RA), ankylosing spondylitis (AS), and juvenile idiopathic poly-articular arthritis (JIA).

Indication: Etanercept is indicated for the treatment of moderately to severely active rheumatoid arthritis in adults and in chronic moderate to severe plaque psoriasis in patients 4 years of age and older. It is also used to manage signs and symptoms of polyarticular idiopathic arthritis and Juvenile Psoriatic Arthritis in those aged 2 years and older. Etanercept is also used to manage the symptoms of psoriatic arthritis and ankylosing spondylitis.

Associated Conditions: Active Juvenile Psoriatic Arthritis, Ankylosing Spondylitis (AS), Graft-versus-host Disease (GVHD), Polyarticular Juvenile Idiopathic Arthritis, Psoriasis Vulgaris (Plaque Psoriasis), Psoriatic Arthritis, Pyoderma Gangrenosum, Rheumatoid Arthritis, Severe Plaque psoriasis, Stevens-Johnson Syndrome, Chronic, severe Psoriatic Arthritis, Moderate Plaque psoriasis, Moderate, active Rheumatoid arthritis, Severe, active Rheumatoid arthritis

Associated Therapies: -

Clinical Trials

STep-up and Step-down Therapeutic Strategies in Childhood ARthritiS

Phase 3

Recruiting

Conditions: Oligoarthritis, Juvenile
Polyarthritis, Juvenile, Rheumatoid Factor Negative

Interventions: Drug: Etanercept
Drug: Methotrexate
Drug: Intra-articular corticosteroid injections

First Posted Date: 2018-11-02

Last Posted Date: 2024-10-11

Lead Sponsor: Istituto Giannina Gaslini

Target Recruit Count: 260

Registration Number: NCT03728478

Locations: 🇮🇹
IRCCS Istituto Giannina Gaslini, Genova, GE, Italy

Pilot Study Evaluating The Efficacy Of Etanercept In Acute Gout

Phase 4

Terminated

Conditions: Gout Attack

Interventions: Drug: Triamcinolone Acetonide
Drug: Etanercept

First Posted Date: 2018-08-17

Last Posted Date: 2023-10-27

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 5

Registration Number: NCT03636373

Locations: 🇺🇸
Rutgers, Robert Wood Johnson Medical School, Clinical Research Center, New Brunswick, New Jersey, United States

Risk of Tuberculous and Other Infections in Patients of Spondyloarthritis Treated With Tofacitinib in Bangladesh

Phase 4

Conditions: Spondyloarthritis

Interventions: Drug: Etanercept
Drug: Tofacitinib 5 mg,

First Posted Date: 2018-04-20

Last Posted Date: 2018-04-23

Lead Sponsor: Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

Target Recruit Count: 174

Registration Number: NCT03504072

Locations: 🇧🇩
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants

Phase 3

Active, not recruiting

Conditions: Psoriasis

Interventions: Drug: Guselkumab
Drug: Placebo for guselkumab
Drug: Etanercept

First Posted Date: 2018-03-02

Last Posted Date: 2024-12-09

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 120

Registration Number: NCT03451851

Locations: 🇩🇪
Universitatsklinikum Carl Gustav Carcus Dresden, Dresden, Germany
🇩🇪
Universitatsklinikum Frankfurt, Frankfurt, Germany
🇨🇦
Kirk Barber Reseach Inc., Calgary, Alberta, Canada

and more 36 locations